Nomura Raises HANSOH PHARMA's Target Price to HKD37.87 Following Increased Revenue and Earnings Projections
Company Performance: HANSOH PHARMA expects a 10% growth in both revenue and earnings for FY26, with a projected 27% YoY revenue increase in 2H25 to RMB7.3 billion, driven by a 17% growth in drug sales.
Analyst Forecasts: Nomura has raised its FY25 revenue and earnings forecasts for HANSOH PHARMA by 1% and 4.7% respectively, adjusting for higher collaboration revenue, and has increased the target price from HKD35.5 to HKD37.87 while maintaining a Neutral rating.
Trade with 70% Backtested Accuracy
Analyst Views on 03692
About the author
Nomura Raises HANSOH PHARMA's Target Price to HKD37.87 Following Increased Revenue and Earnings Projections
Company Performance: HANSOH PHARMA expects a 10% growth in both revenue and earnings for FY26, with a projected 27% YoY revenue increase in 2H25 to RMB7.3 billion, driven by a 17% growth in drug sales.
Analyst Forecasts: Nomura has raised its FY25 revenue and earnings forecasts for HANSOH PHARMA by 1% and 4.7% respectively, adjusting for higher collaboration revenue, and has increased the target price from HKD35.5 to HKD37.87 while maintaining a Neutral rating.
UOB Kay Hian Supports ALI HEALTH and PA GOODDOCTOR as AI Innovations and National Policies Propel China's Internet Healthcare Industry
Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.
Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.
Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.
Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.
G Sachs: This Year, China's Healthcare Sector Depends More on Data and Earnings Clarity; Favorable Outlook for CDMO Companies
Healthcare Sector Outlook: Goldman Sachs predicts that the strong trend in China's healthcare sector will continue, with stock trading increasingly focused on companies' execution capabilities and R&D pipelines rather than just licensing expectations.
CDMO Companies Favorable: The broker is optimistic about CDMO companies due to their growth potential and reasonable valuations, upgrading WUXI APPTEC and WUXI XDC to Buy.
Selective Biotech and Pharma Strategy: Goldman Sachs favors biotech and pharmaceutical companies with promising data releases and transaction expectations, highlighting SKB BIO-B, HENLIUS, and HANSOH PHARMA as favorable investments.
Cautious on Medical Services: The broker maintains a neutral stance on the medical devices sector and is cautious about medical services due to cost control measures and weak consumption, downgrading HYGEIA HEALTH and JXR to Neutral/Sell.
HANSOH PHARMA Shares Drop 4.92% Following Announcement of HKD4.68B Convertible Bond Issuance
Stock Performance: Hansoh Pharma's stock opened down 1.04% and traded at HKD38.26, reflecting a decline of 4.92% with significant short selling activity amounting to $44.60 million.
Convertible Bonds Issuance: The company announced a proposed issuance of HKD4.68 billion in zero-coupon convertible bonds due in 2033, with a conversion price set at HKD57.39, representing a 42.62% premium over the previous day's closing price.
HSI Rises by 97 Points; ANTA SPORTS Sees Gains; ZIJIN MINING Jumps 4%
Market Overview: The HSI opened 0.4% higher at 26,863, with the HSCEI and HSTECH also showing slight gains at 9,173 and 5,734, respectively.
Tech Stock Movements: BABA-W launched a new reasoning model and opened up 1%, while other major tech stocks like TENCENT and KUAISHOU-W saw minor increases, whereas JD-SW and BIDU-SW experienced slight declines.
Automotive Sector Updates: BYD and NIO both saw a 1% increase, while XIAOMI-W also grew slightly, indicating positive movement in the automotive market.
Significant Corporate Actions: ANTA SPORTS became Puma's largest shareholder with a 29% stake acquisition, while ZIJIN GOLD INTL surged 12.165% after announcing plans to take over Allied Gold for RMB28 billion.
HANSOH PHARMA Launches $4.68 Billion Zero Coupon Convertible Bonds
Bond Issuance Announcement: Hansoh Pharma announced a proposal to issue zero coupon convertible bonds worth $4.68 billion, maturing in 2033, with an initial conversion price set at $57.39, a 42.62% premium over the previous closing price.
Use of Proceeds: The net proceeds from the bond issuance, estimated at approximately $4.64 billion, will be allocated primarily to drug R&D (65%), construction of new R&D centers and production lines (25%), and general corporate purposes (10%).
Nomura Raises HANSOH PHARMA's Target Price to HKD37.87 Following Increased Revenue and Earnings Projections
Company Performance: HANSOH PHARMA expects a 10% growth in both revenue and earnings for FY26, with a projected 27% YoY revenue increase in 2H25 to RMB7.3 billion, driven by a 17% growth in drug sales.
Analyst Forecasts: Nomura has raised its FY25 revenue and earnings forecasts for HANSOH PHARMA by 1% and 4.7% respectively, adjusting for higher collaboration revenue, and has increased the target price from HKD35.5 to HKD37.87 while maintaining a Neutral rating.
UOB Kay Hian Supports ALI HEALTH and PA GOODDOCTOR as AI Innovations and National Policies Propel China's Internet Healthcare Industry
Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.
Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.
Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.
Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.
G Sachs: This Year, China's Healthcare Sector Depends More on Data and Earnings Clarity; Favorable Outlook for CDMO Companies
Healthcare Sector Outlook: Goldman Sachs predicts that the strong trend in China's healthcare sector will continue, with stock trading increasingly focused on companies' execution capabilities and R&D pipelines rather than just licensing expectations.
CDMO Companies Favorable: The broker is optimistic about CDMO companies due to their growth potential and reasonable valuations, upgrading WUXI APPTEC and WUXI XDC to Buy.
Selective Biotech and Pharma Strategy: Goldman Sachs favors biotech and pharmaceutical companies with promising data releases and transaction expectations, highlighting SKB BIO-B, HENLIUS, and HANSOH PHARMA as favorable investments.
Cautious on Medical Services: The broker maintains a neutral stance on the medical devices sector and is cautious about medical services due to cost control measures and weak consumption, downgrading HYGEIA HEALTH and JXR to Neutral/Sell.
HANSOH PHARMA Shares Drop 4.92% Following Announcement of HKD4.68B Convertible Bond Issuance
Stock Performance: Hansoh Pharma's stock opened down 1.04% and traded at HKD38.26, reflecting a decline of 4.92% with significant short selling activity amounting to $44.60 million.
Convertible Bonds Issuance: The company announced a proposed issuance of HKD4.68 billion in zero-coupon convertible bonds due in 2033, with a conversion price set at HKD57.39, representing a 42.62% premium over the previous day's closing price.
HSI Rises by 97 Points; ANTA SPORTS Sees Gains; ZIJIN MINING Jumps 4%
Market Overview: The HSI opened 0.4% higher at 26,863, with the HSCEI and HSTECH also showing slight gains at 9,173 and 5,734, respectively.
Tech Stock Movements: BABA-W launched a new reasoning model and opened up 1%, while other major tech stocks like TENCENT and KUAISHOU-W saw minor increases, whereas JD-SW and BIDU-SW experienced slight declines.
Automotive Sector Updates: BYD and NIO both saw a 1% increase, while XIAOMI-W also grew slightly, indicating positive movement in the automotive market.
Significant Corporate Actions: ANTA SPORTS became Puma's largest shareholder with a 29% stake acquisition, while ZIJIN GOLD INTL surged 12.165% after announcing plans to take over Allied Gold for RMB28 billion.
HANSOH PHARMA Launches $4.68 Billion Zero Coupon Convertible Bonds
Bond Issuance Announcement: Hansoh Pharma announced a proposal to issue zero coupon convertible bonds worth $4.68 billion, maturing in 2033, with an initial conversion price set at $57.39, a 42.62% premium over the previous closing price.
Use of Proceeds: The net proceeds from the bond issuance, estimated at approximately $4.64 billion, will be allocated primarily to drug R&D (65%), construction of new R&D centers and production lines (25%), and general corporate purposes (10%).
